## Yang-Liu Xia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5144612/publications.pdf

Version: 2024-02-01

713332 687220 30 506 13 21 citations h-index g-index papers 31 31 31 499 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Withaferin A alleviates ethanol-induced liver injury by inhibiting hepatic lipogenesis. Food and Chemical Toxicology, 2022, 160, 112807.	1.8	6
2	Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis. Cancer Chemotherapy and Pharmacology, 2022, 89, 173-181.	1.1	7
3	Analytical methodologies for sensing catechol-O-methyltransferase activity and their applications. Journal of Pharmaceutical Analysis, 2021, 11, 15-27.	2.4	5
4	Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment. Bioorganic and Medicinal Chemistry, 2021, 29, 115851.	1.4	16
5	Discovery and characterization of naturally occurring potent inhibitors of catechol- <i>O</i> -methyltransferase from herbal medicines. RSC Advances, 2021, 11, 10385-10392.	1.7	3
6	Combined analysis of metagenomic data revealed consistent changes of gut microbiome structure and function in inflammatory bowel disease. Journal of Applied Microbiology, 2021, 131, 3018-3031.	1.4	14
7	The pathophysiological function of non-gastrointestinal farnesoid X receptor., 2021, 226, 107867.		26
8	Withaferin A in the treatment of liver diseases: progress and pharmacokinetic insights. Drug Metabolism and Disposition, 2021, , DMD-MR-2021-000455.	1.7	8
9	Accurate and sensitive detection of Catechol-O-methyltransferase activity by liquid chromatography with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1157, 122333.	1.2	5
10	<i>In vitro</i> characterization of the glucuronidation pathways of licochalcone A mediated by human UDP-glucuronosyltransferases. Xenobiotica, 2019, 49, 671-677.	0.5	4
11	Preparation of an Electrically Conductive Graphene Oxide/Chitosan Scaffold for Cardiac Tissue Engineering. Applied Biochemistry and Biotechnology, 2019, 188, 952-964.	1.4	90
12	Glucuronidation of d-Luciferin In Vitro: Isoform Selectivity and Kinetics Characterization. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 549-556.	0.6	1
13	Recent progress and challenges in screening and characterization of UGT1A1 inhibitors. Acta Pharmaceutica Sinica B, 2019, 9, 258-278.	5 <b>.</b> 7	61
14	<i>In vitro</i> evaluation of the effect of C-4 substitution on methylation of 7,8-dihydroxycoumarin: metabolic profile and catalytic kinetics. Royal Society Open Science, 2018, 5, 171271.	1.1	7
15	Identification and characterization of human UDP-glucuronosyltransferases responsible for xanthotoxol glucuronidation. Xenobiotica, 2018, 48, 109-116.	0.5	11
16	Synthesis and Structure-Activity Relationship of Daphnetin Derivatives as Potent Antioxidant Agents. Molecules, 2018, 23, 2476.	1.7	19
17	Interspecies comparison in the COMT-mediated methylation of 3-BTD. RSC Advances, 2018, 8, 16278-16284.	1.7	3
18	An Optimized Twoâ€Photon Fluorescent Probe for Biological Sensing and Imaging of Catecholâ€ <i>O</i> â€Methyltransferase. Chemistry - A European Journal, 2017, 23, 10800-10807.	1.7	32

#	Article	lF	CITATION
19	Inhibition of human catechol- <i>O</i> -methyltransferase-mediated dopamine <i>O</i> -methylation by daphnetin and its Phase II metabolites. Xenobiotica, 2017, 47, 498-504.	0.5	12
20	A highly selective fluorescent probe for sensing activities of catechol- O -methyltransferase in complex biological samples. Sensors and Actuators B: Chemical, 2016, 231, 615-623.	4.0	15
21	Methylation, Glucuronidation, and Sulfonation of Daphnetin in Human Hepatic Preparations InÂVitro : Metabolic Profiling, Pathway Comparison, and Bioactivity Analysis. Journal of Pharmaceutical Sciences, 2016, 105, 808-816.	1.6	21
22	C-8 Mannich base derivatives of baicalein display improved glucuronidation stability: exploring the mechanism by experimentation and theoretical calculations. RSC Advances, 2015, 5, 89818-89826.	1.7	10
23	In Vitro Evaluation of the Effect of 7-Methyl Substitution on Glucuronidation of Daphnetin: Metabolic Stability, Isoform Selectivity, and Bioactivity Analysis. Journal of Pharmaceutical Sciences, 2015, 104, 3557-3564.	1.6	9
24	Identification and characterization of human UDP-glucuronosyltransferases responsible for the in-vitro glucuronidation of arctigenin. Journal of Pharmacy and Pharmacology, 2015, 67, 1673-1681.	1.2	13
25	Design, synthesis and biological evaluation of esculetin derivatives as anti-tumour agents. RSC Advances, 2015, 5, 53477-53483.	1.7	20
26	Diethylstilbestrol can effectively accelerate estradiol-17-O-glucuronidation, while potently inhibiting estradiol-3-O-glucuronidation. Toxicology and Applied Pharmacology, 2015, 283, 109-116.	1.3	18
27	Tissue and species differences in the glucuronidation of glabridin with UDP-glucuronosyltransferases. Chemico-Biological Interactions, 2015, 231, 90-97.	1.7	12
28	Structural Modifications at the C-4 Position Strongly Affect the Glucuronidation of 6,7-Dihydroxycoumarins. Drug Metabolism and Disposition, 2015, 43, 553-560.	1.7	14
29	Glucuronidation of bavachinin by human tissues and expressed UGT enzymes: Identification of UGT1A1 and UGT1A8 as the major contributing enzymes. Drug Metabolism and Pharmacokinetics, 2015, 30, 358-365.	1.1	17
30	Identification and Characterization of Human UDP-glucuronosyltransferases Responsible for the Glucuronidation of Fraxetin. Drug Metabolism and Pharmacokinetics, 2014, 29, 135-140.	1.1	27